BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

423 related articles for article (PubMed ID: 33617838)

  • 1. Pentraxin 3 acts as a functional effector of Akt/NF-κB signaling to modulate the progression and cisplatin-resistance in non-small cell lung cancer.
    Li Y; Song X; Niu J; Ren M; Tang G; Sun Z; Kong F
    Arch Biochem Biophys; 2021 Apr; 701():108818. PubMed ID: 33617838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Upregulation of Long Noncoding RNA (lncRNA) X-Inactive Specific Transcript (XIST) is Associated with Cisplatin Resistance in Non-Small Cell Lung Cancer (NSCLC) by Downregulating MicroRNA-144-3p.
    Tian LJ; Wu YP; Wang D; Zhou ZH; Xue SB; Zhang DY; Wei YG; Liu W
    Med Sci Monit; 2019 Oct; 25():8095-8104. PubMed ID: 31659146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Knockdown of KLF5 suppresses hypoxia-induced resistance to cisplatin in NSCLC cells by regulating HIF-1α-dependent glycolysis through inactivation of the PI3K/Akt/mTOR pathway.
    Gong T; Cui L; Wang H; Wang H; Han N
    J Transl Med; 2018 Jun; 16(1):164. PubMed ID: 29898734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circ_PIP5K1A regulates cisplatin resistance and malignant progression in non-small cell lung cancer cells and xenograft murine model via depending on miR-493-5p/ROCK1 axis.
    Feng N; Guo Z; Wu X; Tian Y; Li Y; Geng Y; Yu Y
    Respir Res; 2021 Sep; 22(1):248. PubMed ID: 34537072
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TRIM59 knockdown blocks cisplatin resistance in A549/DDP cells through regulating PTEN/AKT/HK2.
    He R; Liu H
    Gene; 2020 Jul; 747():144553. PubMed ID: 32165307
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
    Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
    [TBL] [Abstract][Full Text] [Related]  

  • 7. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
    Gao BB; Wang SX
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rg3 inhibits gemcitabine-induced lung cancer cell invasiveness through ROS-dependent, NF-κB- and HIF-1α-mediated downregulation of PTX3.
    Ahmmed B; Kampo S; Khan M; Faqeer A; Kumar SP; Yulin L; Liu JW; Yan Q
    J Cell Physiol; 2019 Jul; 234(7):10680-10697. PubMed ID: 30628067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tunicamycin enhances the suppressive effects of cisplatin on lung cancer growth through PTX3 glycosylation via AKT/NF-κB signaling pathway.
    Ahmmed B; Khan MN; Nisar MA; Kampo S; Zheng Q; Li Y; Yan Q
    Int J Oncol; 2019 Feb; 54(2):431-442. PubMed ID: 30483742
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CHD1L contributes to cisplatin resistance by upregulating the ABCB1-NF-κB axis in human non-small-cell lung cancer.
    Li Y; He LR; Gao Y; Zhou NN; Liu Y; Zhou XK; Liu JF; Guan XY; Ma NF; Xie D
    Cell Death Dis; 2019 Feb; 10(2):99. PubMed ID: 30718500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. XPC inhibition rescues cisplatin resistance via the Akt/mTOR signaling pathway in A549/DDP lung adenocarcinoma cells.
    Teng X; Fan XF; Li Q; Liu S; Wu DY; Wang SY; Shi Y; Dong M
    Oncol Rep; 2019 Mar; 41(3):1875-1882. PubMed ID: 30628719
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-25-3p promotes cisplatin resistance in Non-small-cell lung carcinoma (NSCLC) through adjusting PTEN/PI3K/AKT route.
    Sun B; Hu N; Cong D; Chen K; Li J
    Bioengineered; 2021 Dec; 12(1):3219-3228. PubMed ID: 34266345
    [TBL] [Abstract][Full Text] [Related]  

  • 13. IOX-101 Reverses Drug Resistance Through Suppression of Akt/mTOR/NF-κB Signaling in Cancer Stem Cell-Like, Sphere-Forming NSCLC Cell.
    Fayi MA; Alamri A; Rajagopalan P
    Oncol Res; 2020 Mar; 28(2):177-189. PubMed ID: 31771696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Knockdown of TRIM65 inhibits autophagy and cisplatin resistance in A549/DDP cells by regulating miR-138-5p/ATG7.
    Pan X; Chen Y; Shen Y; Tantai J
    Cell Death Dis; 2019 Jun; 10(6):429. PubMed ID: 31160576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circular RNA hsa_circ_0096157 contributes to cisplatin resistance by proliferation, cell cycle progression, and suppressing apoptosis of non-small-cell lung carcinoma cells.
    Lu H; Xie X; Wang K; Chen Q; Cai S; Liu D; Luo J; Kong J
    Mol Cell Biochem; 2020 Dec; 475(1-2):63-77. PubMed ID: 32767026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LncRNA NNT-AS1 is a major mediator of cisplatin chemoresistance in non-small cell lung cancer through MAPK/Slug pathway.
    Cai Y; Dong ZY; Wang JY
    Eur Rev Med Pharmacol Sci; 2018 Aug; 22(15):4879-4887. PubMed ID: 30070323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hesperetin reverses P‑glycoprotein‑mediated cisplatin resistance in DDP‑resistant human lung cancer cells via modulation of the nuclear factor‑κB signaling pathway.
    Kong W; Ling X; Chen Y; Wu X; Zhao Z; Wang W; Wang S; Lai G; Yu Z
    Int J Mol Med; 2020 Apr; 45(4):1213-1224. PubMed ID: 32124932
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Depleted aldehyde dehydrogenase 1A1 (ALDH1A1) reverses cisplatin resistance of human lung adenocarcinoma cell A549/DDP.
    Wei Y; Wu S; Xu W; Liang Y; Li Y; Zhao W; Wu J
    Thorac Cancer; 2017 Jan; 8(1):26-32. PubMed ID: 27813328
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ELF1 activated long non-coding RNA CASC2 inhibits cisplatin resistance of non-small cell lung cancer via the miR-18a/IRF-2 signaling pathway.
    Xiao XH; He SY
    Eur Rev Med Pharmacol Sci; 2020 Mar; 24(6):3130-3142. PubMed ID: 32271431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.